Medivir 2022 Annual Report published
Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the company’s website: www.medivir.com. Medivir's cutting edge project fostrox has the potential to become the first liver-targeted, orally administered drug to help patients with various cancers of the liver, an area of great medical need. The clinical development of fostrox has been in focus in 2022 with a high recruitment rate in the second half of the year, which enabled the phase 2a part of the study, with fostrox in combination with Lenvima®, to start at the